Therapeutic agents
The invention provides well-defined compounds that are either EP 2 agonists, EP 4 agonists, or mixed EP 2 /EP 4 agonist. The compounds are useful for treating a variety of pathological conditions associated with activity of the EP 2 and/or EP 4 receptors.
1. A method of treating glaucoma, the method comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound having the structure:
or a pharmaceutically acceptable salt thereof, wherein:
Ar is aryl, heteroaryl, substituted aryl, or substituted heteroaryl, wherein substituents are selected from alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxyl, alkoxy, halogen, —CN, —CF 3 , —C(O)R 1 , —C(O)OR 1 , —C(O)CF 3 , —SO 2 N(R 1 ) 2 , —SO 2 NH 2 , or —NO 2 ;
L is C 1 -C 6 alkylene;
A is arylene or heteroarylene;
E is —CO 2 R 1 , —CH 2 OR 1 , —C(O)N(R 1 ) 2 , or tetrazol-5-yl;
each R 1 is independently H, C 1 -C 6 alkyl, phenyl, or biphenyl; and
n is 0 or 1.
2. The method of claim 1 , wherein the compound administered is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.